GonGlobal (H10x)
Radically improving the IVF patient experience and treatment success rates.
Founded in 2023, GonGlobal will radically improve the in vitro fertilization (IVF) patient experience and treatment success rates by replacing the injected forms of the five approved key infertility drugs with pain-free, non-invasive delivery through a cloud-connected device. This will enable real-time communication between clinicians and patients to ensure adherence to treatment protocols and greater personalization of healthcare. For patients, injection related anxiety is the second greatest barrier to IVF treatment. Key opinion leaders have identified non-invasive IVF treatments as a top unmet need. GonGlobal is uniquely positioned to meet this challenge and expand the overall IVF market.
Achievements:
Established an advisory board comprising global experts in IVF, development of non-invasive, painless drug delivery methods, stress biology, manufacturing, preclinical and clinical development, drug regulations, commercialization, software development, and data analytics (ML/AI).
Designed clinical protocol and sourced CRO estimates for lead drug, designed proof of concept study for second drug.
Raising funds in parallel with Health 10x to test device and formulation development for lead drug, begin app development, and test second drug proof of concept.
Ellen Gonda, Co-Founder & CEO; Dr Igor Gonda, Co-Founder & CSO.